Control of chemotherapy-induced nausea, once an elusive prospect, is increasingly successful with the use of an approved drug commonly used by psychiatrists, according to conclusive findings in a new study by Rudy Navari, assistant dean and director of the Indiana University School of Medicine-South Bend and clinical director of the Harper Cancer Research Institute.

Navari’s Phase III study demonstrates that the antipsychotic drug Olanzapine, used in conjunction with standard antiemetics during the administration of chemotherapy, curbs vomiting and significantly reduces nausea, and at a lesser cost  than the use of the current standard antiemetic regimen using the drug Aprepitant. (Read more about the study.)